DrugPatentWatch Database Preview
Covis Pharma Bv Company Profile
What is the competitive landscape for COVIS PHARMA BV, and when can generic versions of COVIS PHARMA BV drugs launch?
There are two US patents protecting COVIS PHARMA BV drugs.
There are twenty-eight patent family members on COVIS PHARMA BV drugs in nineteen countries and five supplementary protection certificates in two countries.
Summary for Covis Pharma Bv
| International Patents: | 28 |
| US Patents: | 2 |
| Tradenames: | 9 |
| Ingredients: | 7 |
| NDAs: | 9 |
Drugs and US Patents for Covis Pharma Bv
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Covis Pharma Bv | BETAPACE | sotalol hydrochloride | TABLET;ORAL | 019865-005 | Apr 20, 1994 | AB1 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ||||
| Covis Pharma Bv | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-003 | Feb 2, 1995 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Covis Pharma Bv | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-008 | Jan 2, 2008 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ||||
| Covis Pharma Bv | RILUTEK | riluzole | TABLET;ORAL | 020599-001 | Dec 12, 1995 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Covis Pharma Bv
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Covis Pharma Bv | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-007 | Jan 2, 2008 | 5,626,874 | ➤ Sign Up |
| Covis Pharma Bv | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-007 | Jan 2, 2008 | 5,422,123 | ➤ Sign Up |
| Covis Pharma Bv | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-001 | Jun 26, 2002 | 6,485,748 | ➤ Sign Up |
| Covis Pharma Bv | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-001 | Jun 26, 2002 | 5,916,595 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for COVIS PHARMA BV drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 20 mg and 30 mg | ➤ Subscribe | 2007-11-07 |
| ➤ Subscribe | Extended-release Tablets | 40 mg | ➤ Subscribe | 2007-06-11 |
| ➤ Subscribe | Extended-release Tablets | 8.5 mg and 17 mg | ➤ Subscribe | 2009-03-02 |
| ➤ Subscribe | Extended-release Tablets | 25.5 mg and 34 mg | ➤ Subscribe | 2008-11-28 |
| ➤ Subscribe | Capsules | 2 mg, 4 mg and 6 mg | ➤ Subscribe | 2007-08-10 |
Non-Orange Book US Patents for Covis Pharma Bv
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,440,387 | Methods for determining risk of Alzheimer's disease | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Covis Pharma Bv Drugs
Supplementary Protection Certificates for Covis Pharma Bv Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 12/048 | Ireland | ➤ Sign Up | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
| C/GB11/013 | United Kingdom | ➤ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| 11/016 | Ireland | ➤ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105 |
| C/GB11/015 | United Kingdom | ➤ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
